It is with mixed feelings that we write this first annual review of our Prime Stocks performance. When we flagged off stock recommendations as a new addition to our platform on January 14 2021, it was after a lot of internal debate on whether it was the right time to do this.
Prime Stocks performance review – 2021 Read More »
In our stock recommendations for 2021, our focus was on identifying companies that had the ability to steadily compound earnings over the medium to long term. Valuations were the other key factor against which we balanced earnings.
Prime Stocks 2021 review: How earnings shaped up & stock outlook Read More »
Here is a look at the diagnostics sector space, the key players, how they have weathered the Covid storm and, more importantly, where it could be headed.
Diagnostics sector review – is it a high growth sector to watch? Read More »
One such reputed family-owned business empire in India has been the Godrej group, founded in 1897. Starting from “lock” manufacturing, the company diversified into soap manufacturing in 1928 (from vegetable oils) and then to animal feeds, real estate, processed foods and chemicals.
The planned split in the Godrej Group: What to expect Read More »
Star Health and Allied Insurance Co Ltd (Star Health), India’s leading standalone health insurer, is making an IPO worth Rs. 7,249 crore comprising a fresh issue of shares valued at Rs.2,000 crore and an offer for sale of Rs.5,249 crore. The issue will open on November 30 and close on December 2 at a price band of Rs. 870-900 per share. At the upper end of the price band, Star Health will be valued at Rs. 51,800 crore (~$7 billion).
IPO Review: Star Health and Allied Insurance Co Ltd Read More »
The Nippon India Taiwan Equity Fund will invest in the new Taiwan dollar (NRD) currency. It is noteworthy that this currency has appreciated by about 5% annually against the rupee over a 10-year period.
NFO Review: Nippon India Taiwan Equity Fund – ride the chip shortage Read More »
Initial Public Offer. IPO. The magic term that brings forward so many emotions…and probably all falling into the bucket of ‘greed’ or ‘fear’. Nothing in between.
IPO/OFS – It’s seller vs buyer, with advantage seller Read More »
Gateway Distriparks (GDL) is a prominent company in the logistics sector. What started off as a single container freight station (CFS) facility to serve containerized imports of paper rolls to India in 1994, post the economic reforms of 1991, transformed into a key logistics player in India’s export-import (EXIM) trade.
Gateway Distriparks (GDL): A long haul on India’s trade and infrastructure Read More »
Rs 18,300 crore. This monumental sum is what One 97 Communications Limited, which owns the Paytm platform, aims to mop up in the largest-ever IPO in our markets. To put it in perspective, it is almost twice the size of the largest IPO this year (Zomato at Rs 9375 cr), and as much as the 3 IPOs that we covered recently (Nykaa, FinoBank and PolicyBazaar) combined.
IPO Review : One 97 Communications (Paytm) Read More »
At a time when the revenue models for many fintech startups are ambiguous, PB Fintech – the company that houses Policybazaar and Paisabazaar – stands out. It has a clear revenue model driven by scalability that will likely pave the path to profits!
IPO review: PB Fintech (Policybazaar) – Should you invest? Read More »
Fino Payments Bank arrives in the market today with an IPO – a public issue of Rs.1,200 crore comprising fresh issue of shares worth Rs.300 crore and offer for sale of shares worth Rs.900 crore by promoter, Fino Paytech, at a price band of Rs. 560-577 per share. The issue opens on October 29 and closes on November 2. The proceeds from the fresh issue will go towards augmenting the capital base of the bank.
IPO Review: Fino Payments Bank Ltd Read More »
FSN E-commerce Ventures, which operates e-commerce platforms in the beauty and fashion spaces under the brand name Nykaa, is launching a Rs 5,350 crore IPO that comprises a fresh issue of shares of Rs 630 crore and an offer for sale of Rs 4,720 crore.
IPO Review: FSN E-Commerce Ventures (Nykaa) Read More »
The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research services before onboarding. History, Present business and Background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services. Terms and conditions of Research Services: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Analyst never guarantees the returns on the recommendation provided. Investor shall take note that Investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The Research Analyst shall not be responsible for any loss to the Investors. Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made there under against the Research Analyst relating to Research Analyst services. Details of its associates: No associates. Disclosures with respect to Research and Recommendations Services: The Research Analyst or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of Research Analyst services. Such conflict of interest shall be disclosed to the client as and when they arise. Research Analyst or its directors or its employee or its associates have not received any compensation from the company which is subject matter of recommendation. Research Analyst or its directors or its employee or its associates have not managed or co-managed the public offering of any company. Research Analyst or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation. The subject company was not a client of Research Analyst or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided. Research Analysts or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.
Full disclosures and disclaimers
Compliance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
Grievance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
